| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015919599 |
| P356 | DOI | 10.1007/S12017-015-8362-X |
| P698 | PubMed publication ID | 26224516 |
| P2093 | author name string | Bernadette Kalman | |
| Katalin Eder | |||
| P2860 | cites work | Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. | Q48380068 |
| Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro | Q48575545 | ||
| A vaccine targeting mutant IDH1 induces antitumour immunity | Q48649314 | ||
| Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. | Q48973528 | ||
| Roots and stems: stem cells in cancer | Q53348663 | ||
| Immune infiltrates and cytokines in gliomas | Q53458549 | ||
| Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. | Q55466463 | ||
| T-lymphocyte entry into the central nervous system | Q70156307 | ||
| The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain | Q71674757 | ||
| Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours | Q72076849 | ||
| Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer | Q73311980 | ||
| The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues | Q79484960 | ||
| Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance | Q80410939 | ||
| Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy | Q80914233 | ||
| The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA | Q21245321 | ||
| Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers | Q24614672 | ||
| Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients | Q26861832 | ||
| New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma | Q26863394 | ||
| Immunotherapy advances for glioblastoma | Q26866513 | ||
| Altered histone modifications in gliomas | Q27027924 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| Identification of a cancer stem cell in human brain tumors | Q28131688 | ||
| The three Es of cancer immunoediting | Q28251475 | ||
| Extensive modulation of a set of microRNAs in primary glioblastoma | Q28263314 | ||
| microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma | Q28280337 | ||
| Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma | Q28286168 | ||
| Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis | Q28305755 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases | Q28507226 | ||
| Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes | Q29547633 | ||
| Paradoxical roles of the immune system during cancer development | Q29614305 | ||
| RNA maps reveal new RNA classes and a possible function for pervasive transcription | Q29614334 | ||
| Macrophages, innate immunity and cancer: balance, tolerance, and diversity | Q29614352 | ||
| Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma | Q29615607 | ||
| Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication | Q29615670 | ||
| Macrophage diversity enhances tumor progression and metastasis | Q29615847 | ||
| Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor | Q29617062 | ||
| Non-coding RNAs: regulators of disease | Q29618040 | ||
| Extracellular vesicles: exosomes, microvesicles, and friends | Q29618137 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 | Q29620608 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
| Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas | Q33361466 | ||
| The transcriptional network for mesenchymal transformation of brain tumours. | Q33572162 | ||
| Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells | Q33604925 | ||
| Tumor-cell-derived microvesicles as carriers of molecular information in cancer | Q38060974 | ||
| Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? | Q38062793 | ||
| From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. | Q38078391 | ||
| Immunological challenges for peptide-based immunotherapy in glioblastoma | Q38142484 | ||
| Glioblastoma and other malignant gliomas: a clinical review. | Q38160159 | ||
| Myeloid-derived suppressor cells in glioma | Q38161536 | ||
| Genetically modified T cells to target glioblastoma | Q38178690 | ||
| The role of regulatory T-cells in glioma immunology. | Q38192273 | ||
| Emerging insights into barriers to effective brain tumor therapeutics | Q38237653 | ||
| The future of glioblastoma therapy: synergism of standard of care and immunotherapy | Q38255481 | ||
| Mitochondrial energy metabolism and apoptosis regulation in glioblastoma | Q38275798 | ||
| Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. | Q38277068 | ||
| Dendritic Cell-Derived Exosomes may be a Tool for Cancer Immunotherapy by Converting Tumor Cells into Immunogenic Targets | Q38342134 | ||
| LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis | Q38497822 | ||
| Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. | Q38895952 | ||
| Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance | Q38973960 | ||
| Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. | Q39052920 | ||
| T cells redirected to EphA2 for the immunotherapy of glioblastoma | Q39258646 | ||
| Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic | Q39460640 | ||
| miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. | Q39613292 | ||
| NK cells recognize and kill human glioblastoma cells with stem cell-like properties | Q39876486 | ||
| Redox-signaling transmitted in trans to neighboring cells by melanoma-derived TNF-containing exosomes. | Q40121438 | ||
| Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model | Q40128542 | ||
| TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells | Q40246842 | ||
| Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. | Q40462449 | ||
| RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. | Q40474790 | ||
| T cell adoptive immunotherapy of newly diagnosed gliomas | Q40619438 | ||
| A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape | Q40736274 | ||
| GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. | Q41870476 | ||
| Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy | Q42136663 | ||
| Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class | Q42789833 | ||
| Glioblastoma microvesicles promote endothelial cell proliferation through Akt/beta-catenin pathway. | Q42856814 | ||
| HDAC inhibitors and their potential applications to glioblastoma therapy | Q42937932 | ||
| Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. | Q43487731 | ||
| The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells | Q44610845 | ||
| Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression | Q44887846 | ||
| Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. | Q45945651 | ||
| Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology | Q46175398 | ||
| Systemic T cell adoptive immunotherapy of malignant gliomas | Q47910243 | ||
| Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro | Q48089474 | ||
| Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs | Q48167948 | ||
| Prognostic significance and mechanism of Treg infiltration in human brain tumors. | Q48170914 | ||
| Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? | Q48301491 | ||
| What is immune privilege (not)? | Q48356667 | ||
| An antigen-specific pathway for CD8 T cells across the blood-brain barrier | Q36229670 | ||
| The cancer stem cell subtype determines immune infiltration of glioblastoma | Q36297010 | ||
| Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. | Q36370300 | ||
| Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma | Q36384944 | ||
| IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival | Q36405905 | ||
| Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. | Q36512160 | ||
| Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study | Q36582874 | ||
| Molecularly targeted therapy for malignant glioma | Q36829847 | ||
| TGF-beta in neural stem cells and in tumors of the central nervous system | Q36915130 | ||
| Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails | Q37002174 | ||
| The role of microglia in central nervous system immunity and glioma immunology | Q37206898 | ||
| Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells | Q37278908 | ||
| Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. | Q37279893 | ||
| NK cells and cancer immunosurveillance. | Q37287176 | ||
| Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. | Q37369658 | ||
| Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation | Q37399550 | ||
| Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | Q37435455 | ||
| The role of histone deacetylases (HDACs) in human cancer | Q37453782 | ||
| DNA repair and resistance of gliomas to chemotherapy and radiotherapy | Q37553777 | ||
| Mechanisms of local immunoresistance in glioma | Q37640584 | ||
| New perspectives in glioma immunotherapy. | Q37914269 | ||
| Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis | Q37954910 | ||
| The good, the bad and the ugly: epigenetic mechanisms in glioblastoma | Q38024560 | ||
| Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma | Q38051323 | ||
| Interleukins in glioblastoma pathophysiology: implications for therapy. | Q38051761 | ||
| Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts | Q33606096 | ||
| Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma | Q33613584 | ||
| Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells | Q33715154 | ||
| Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model | Q33903144 | ||
| Tumour-infiltrating T-cell subpopulations in glioblastomas | Q33943553 | ||
| Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor | Q34122292 | ||
| Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. | Q34132823 | ||
| Glioma-associated cancer-initiating cells induce immunosuppression | Q34147415 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs | Q34171631 | ||
| HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment | Q34243443 | ||
| Glioblastoma cells release factors that disrupt blood-brain barrier features | Q34290788 | ||
| CpNpG methylation in mammalian cells | Q34303066 | ||
| A long non-coding RNA signature in glioblastoma multiforme predicts survival. | Q34347963 | ||
| MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape | Q34365811 | ||
| The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes | Q34411026 | ||
| Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. | Q34541564 | ||
| A cytokine-mediated link between innate immunity, inflammation, and cancer | Q34625152 | ||
| Valproic acid use during radiation therapy for glioblastoma associated with improved survival. | Q34633117 | ||
| Engineered antibody fragments and the rise of single domains | Q34650980 | ||
| Blood-brain barrier breakdown in septic encephalopathy and brain tumours | Q34774036 | ||
| MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells | Q34842477 | ||
| Tumor and endothelial cell-derived microvesicles carry distinct CEACAMs and influence T-cell behavior | Q34990225 | ||
| Glioma cancer stem cells induce immunosuppressive macrophages/microglia | Q34992518 | ||
| MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development | Q35036059 | ||
| Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells | Q35052425 | ||
| Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells | Q35111932 | ||
| Natural killer cell receptor signaling | Q35145778 | ||
| New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape | Q35300077 | ||
| miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients | Q35694536 | ||
| In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation | Q35862318 | ||
| Recent advances in the generation of bispecific antibodies for tumor immunotherapy. | Q35986333 | ||
| Inflammation and cancer: is the link as simple as we think? | Q36162462 | ||
| Microglia function in brain tumors | Q36164949 | ||
| MicroRNAs: critical regulators of development, cellular physiology and malignancy | Q36227101 | ||
| P433 | issue | 4 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 335-352 | |
| P577 | publication date | 2015-07-30 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | NeuroMolecular Medicine | Q15716731 |
| P1476 | title | The Dynamics of Interactions Among Immune and Glioblastoma Cells | |
| P478 | volume | 17 |
| Q98945429 | A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model |
| Q90590035 | CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2 |
| Q60938527 | Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma |
| Q92084523 | Complement System in Cutaneous Squamous Cell Carcinoma |
| Q58694904 | Endophytic Fungus Isolated From Exhibits Selective Antiglioma Activity-The Role of Sch-642305 |
| Q48108207 | Fetal microchimerism in human brain tumors. |
| Q38907925 | Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma |
| Q38374300 | Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial |
| Q39044652 | Review of the potential of optical technologies for cancer diagnosis in neurosurgery: a step toward intraoperative neurophotonics |
| Q58748412 | The complement system in glioblastoma multiforme |
Search more.